Behavioural Pharmacology is a distinguished academic journal published by Lippincott Williams & Wilkins, focusing on the intricate relationship between pharmacology, psychiatry, and behavioral science. With an ISSN of 0955-8810 and an E-ISSN of 1473-5849, this journal serves as a vital platform for researchers and professionals dedicated to exploring the pharmacological mechanisms underlying behavior and mental health. Operating with a robust track record since its inception in 1992, it has established itself in the academic community, as reflected by its Q3 rankings in both the pharmacology and psychiatry categories for 2023. Additionally, the journal holds a credible position in Scopus rankings, with a percentile ranking indicative of significant contributions to the fields of pharmacology and psychiatry. Aimed at advancing knowledge and disseminating research in the behavioral pharmacology domain, this journal is an essential resource for students, researchers, and clinical professionals seeking to stay at the forefront of this rapidly evolving field. While it is not an open access journal, the rich content and research findings published here continue to foster collaboration and innovation within the community, making it a crucial reference point for current and future studies.

ASN Neuro is an esteemed academic journal published by Frontiers Media SA, focusing on critical advancements in the fields of neurology and neuroscience. Since its inception in 2009, it has established itself as an Open Access platform dedicated to fostering the dissemination of knowledge and research findings that address the complexities of the nervous system. With an impressive impact factor and consistently ranking in the top quartiles of its categories—Q1 in Neurology (clinical) and Q2 in Neuroscience (miscellaneous)—ASN Neuro is recognized for its high-quality publications that cater to the evolving challenges in clinical neurology and general neuroscience. Currently, it ranks 68th out of 400 journals in Clinical Neurology and 28th out of 113 in General Neuroscience, affirming its reputable position within the academic community. Researchers, professionals, and students alike are encouraged to contribute to and benefit from this impactful journal as it presents a unique opportunity to engage with cutting-edge research, innovative methodologies, and insightful reviews in the ever-evolving landscape of brain science.

Brain Communications is an esteemed, open-access academic journal published by Oxford University Press since 2019, focusing on the dynamic field of neuroscience. With a dedicated ISSN and an E-ISSN of 2632-1297, this journal aims to address the intricate relationships between brain functions, psychiatric disorders, and neurobiological mechanisms. The journal stands out in the academic realm, holding a prestigious Q1 ranking across several categories, including Biological Psychiatry, Cellular and Molecular Neuroscience, Neurology, and Psychiatry and Mental Health for 2023. Notably, it has also secured impressive Scopus ranks in various neuroscience and psychiatry fields, evidencing its commitment to high-quality research. With an impact factor reflective of its growing influence, Brain Communications provides accessible research findings to professionals, researchers, and students alike, fostering a deeper understanding of complex neurological phenomena. This innovative journal is pivotal for anyone involved in advancing knowledge in neuroscience and mental health.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, published by PERGAMON-ELSEVIER SCIENCE LTD, is a leading peer-reviewed journal that serves the interdisciplinary field of neuropsychopharmacology and biological psychiatry. With an impressive impact factor in the first quartile of both Biological Psychiatry and Pharmacology categories, this journal provides a critical platform for the dissemination of cutting-edge research and innovative therapeutic approaches. Covering a broad range of topics from the molecular mechanisms underlying psychiatric disorders to advanced pharmacological interventions, it aims to foster scientific dialogue among researchers, clinicians, and students alike. The journal has been at the forefront of scientific inquiry since its inception in 1982 and continues to evolve, adapting to the ever-changing landscape of neuroscience and mental health research. With its focus on high-quality articles and a commitment to advancing the understanding of neuropsychopharmacology, this journal is essential for anyone interested in the complexities of brain function and mental health.

NEUROSCIENCE RESEARCH, published by Elsevier Ireland Ltd, is a leading journal in the field of neuroscience, with a notable reputation for disseminating high-quality research that spans a variety of topics within the discipline. With an ISSN of 0168-0102 and an E-ISSN of 1872-8111, this journal serves as a vital platform for both established researchers and emerging voices in the field. Ranking in the Q2 quartile in both Medicine and Neuroscience categories, it has been recognized as a reliable source of innovative findings since its inception in 1984, with continuous publication through 2024. Although it does not currently offer Open Access options, the journal is indexed in Scopus, holding a significant position at Rank #48/113 in General Neuroscience, reflecting its contribution to advancing the understanding of neural mechanisms across various contexts. With its address anchored in Ireland, NEUROSCIENCE RESEARCH plays an essential role in bridging scientific inquiry and practical applications, making it an indispensable resource for researchers, professionals, and students dedicated to the burgeoning field of neuroscience.

Biological Psychiatry-Cognitive Neuroscience and Neuroimaging is a leading interdisciplinary journal published by Elsevier, focusing on the convergence of biological psychiatry, cognitive neuroscience, and advanced neuroimaging techniques. With its prestigious Q1 rankings across essential categories such as Biological Psychiatry, Cognitive Neuroscience, and Neurology (clinical), this journal is at the forefront of research that examines the complexities of mental health through innovative methodologies. Covering a broad spectrum of topics from neurobiological mechanisms to clinical applications, it aims to provide a platform for scholars and practitioners to exchange insights on mental disorders and their neurobiological underpinnings. The impact factor and Scopus rankings further underscore its importance, with rankings highlighting its position in the top percentiles of related disciplines. By fostering an open exchange of ideas and promoting cutting-edge research, this journal is an essential resource for researchers, professionals, and students dedicated to advancements in the understanding and treatment of psychiatric and neurological conditions.

FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE is a pivotal journal in the fields of neurology, psychiatry, and related medical disciplines, published by GEORG THIEME VERLAG KG in Germany. With a history dating back to 1955, this journal has evolved to address the dynamic nature of neurological and psychiatric research, offering valuable insights and advancements in the field. Despite holding a Q4 category status in various medical domains according to the 2023 quartiles, the journal continues to foster academic discussion and engagement among researchers and clinicians alike. It serves as a vital platform for disseminating knowledge through original research articles, reviews, and clinical studies, making it an essential resource for professionals and students aiming to stay abreast of the latest developments in mental health and neurological science. Although the journal currently does not offer open access options, its contribution to the academic community is significant, helping to illuminate the intricate relationships between neurological disorders and psychiatric conditions.

General Psychiatry is a leading open-access journal published by BMJ PUBLISHING GROUP, dedicated to advancing the field of psychiatry and mental health. With an impressive impact factor and ranked in the Q1 category across various related disciplines—including Psychiatry and Mental Health, as well as Clinical Neurology—this journal offers a vital platform for researchers and practitioners in the field to disseminate high-quality studies and insights. The journal has been open access since 2018, ensuring that the latest research is freely available to a global audience, thus fostering greater collaboration and innovation. With a focus on significant developments and emerging trends, General Psychiatry serves as an essential resource for professionals keen on improving mental health practices and understanding neurological aspects of mental disorders. The journal is based in the United Kingdom, reflecting a commitment to global health discussions and initiatives in psychiatry.

Current Neuropharmacology is a premier journal dedicated to advancing the field of neuropharmacology, published by Bentham Science Publishers Ltd in the United Arab Emirates. As a leader in its domain, this journal has achieved a remarkable position in 2023, with Q1 rankings across several categories including Medicine (miscellaneous), Neurology, and Pharmacology. With a robust focus on the latest research related to pharmacological treatments and their neurological implications, Current Neuropharmacology features cutting-edge studies that inform clinical practices and psychiatric care. Although not open access, the journal offers both print and electronic formats to cater to a diverse audience of researchers, healthcare professionals, and students keen on accessing vital information in neuropharmacology. Its high impact within the academia is underscored by impressive Scopus rankings, confirming its importance as a vital resource for the ongoing exploration of mental health and neurotherapeutic innovations. With an engaging scope that encompasses emerging discoveries and clinical advancements, Current Neuropharmacology continues to be an essential platform for scholarly communication in the evolving landscape of neuroscience and pharmacology.

PSYCHIATRIC QUARTERLY, published by Springer, stands as a pivotal resource in the field of psychiatry and mental health since its inception in 1927. With a reputable Q2 categorization in Psychiatry and Mental Health for 2023, this journal ranks impressively at #77 out of 567 in Scopus, placing it in the top 86th percentile of its category. Covering a diverse range of topics related to mental health, PSYCHIATRIC QUARTERLY aims to disseminate rigorous research findings, theoretical advancements, and clinical insights that contribute to improved mental health practices and policies. Although it does not offer open access, it provides substantial value to researchers, professionals, and students through its comprehensive analyses and scholarly articles. Located in New York, United States, the journal serves as an essential platform for advancing the understanding and treatment of psychiatric disorders, making it an invaluable addition to any academic library or research portfolio.